| 1 |
Berger J, Hinglais N. Intercapillary deposits of IgA-IgG [J]. J Urol Nephrol, 1968, 74(9):694-695.
|
| 2 |
McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature [J]. Nephrol Dial Transplant, 2011, 26(2):414-430.
|
| 3 |
Varis J, Rantala I, Pasternack A, et al. Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death [J]. J Clin Pathol, 1993, 46(7):607-610.
|
| 4 |
Knoop T, Vikse BE, Svarstad E, et al. Mortality in patients with IgA nephropathy [J]. Am J Kidney Dis, 2013, 62(5):883-890.
|
| 5 |
Canetta PA, Kiryluk K, Appel GB. Glomerular diseases: emerging tests and therapies for IgA nephropathy [J]. Clin J Am Soc Nephrol, 2014, 9(3):617-625.
|
| 6 |
Lai KN. Pathogenesis of IgA nephropathy [J]. Nat Rev Nephrol, 2012, 8(5):275-283.
|
| 7 |
Ji S, Liu M, Chen J, et al. The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation [J]. Clin Transplant, 2004, 18(5):536-540.
|
| 8 |
Mestecky J, Raska M, Julian BA, et al. IgA nephropathy: molecular mechanisms of the disease [J]. Annu Rev Pathol, 2013, 8:217-240.
|
| 9 |
Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy [J]. Kidney Int, 2001, 59(3):1077-1085.
|
| 10 |
Wang L, Li X, Shen H, et al. Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA nephropathy [J]. Sci Rep, 2016, 6:30964.
|
| 11 |
Kiryluk K, Moldoveanu Z, Sanders JT, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis [J]. Kidney Int, 2011, 80(1):79-87.
|
| 12 |
Boyd JK, Cheung CK, Molyneux K, et al. An update on the pathogenesis and treatment of IgA nephropathy [J]. Kidney Int, 2012, 81(9):833-843.
|
| 13 |
Zwirner J, Burg M, Schulze M, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy [J]. Kidney Int, 1997, 51(4):1257-1264.
|
| 14 |
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility [J]. Kidney Int, 2009, 76(5):546-556.
|
| 15 |
Donadio JV, Grande JP. IgA nephropathy [J]. N Engl J Med, 2002, 347(10):738-748.
|
| 16 |
Maixnerova D, Reily C, Bian Q, et al. Markers for the progression of IgA nephropathy [J]. J Nephrol, 2016, 29(4):535-541.
|
| 17 |
Zhao YF, Zhu L, Liu LJ, et al. Measures of urinary protein and albumin in the prediction of progression of IgA nephropathy [J]. Clin J Am Soc Nephrol, 2016, 11(6):947-955.
|
| 18 |
Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens [J]. Nat Genet, 2014, 46(11):1187-1196.
|
| 19 |
Li M, Foo JN, Wang JQ, et al. Identification of new susceptibility loci for IgA nephropathy in Han Chinese [J]. Nat Commun, 2015, 6:7270.
|
| 20 |
Nakata J, Suzuki Y, Suzuki H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy [J]. PLoS One, 2014, 9(2):e89707.
|
| 21 |
Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy [J]. J Am Soc Nephrol, 2012, 23(9):1579-1587.
|
| 22 |
Berthelot L, Robert T, Vuiblet V, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes [J]. Kidney Int, 2015, 88(4):815-822.
|
| 23 |
Ranieri E, Gesualdo L, Petrarulo F, et al. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy [J]. Kidney Int, 1996, 50(6):1990-2001.
|
| 24 |
Duan ZY, Cai GY, Bu R, et al. Selection of urinary sediment miRNAs as specific biomarkers of IgA nephropathy [J]. Sci Rep, 2016, 6:23498.
|
| 25 |
Herzenberg AM, Fogo AB, Reich HN, et al. Validation of the Oxford classification of IgA nephropathy [J]. Kidney Int, 2011, 80(3):310-317.
|
| 26 |
Harada K, Akai Y, Yamaguchi Y, et al. Prediction of corticosteroid responsiveness based on fibroblast-specific protein 1 (FSP1) in patients with IgA nephropathy [J]. Nephrol Dial Transplant, 2008, 23(10):3152-3159.
|
| 27 |
Du R, Zhao L, Xia L, et al. Association of URG11 and Twist with clinical pathological characteristics and prognosis in patients with IgA nephropathy [J]. Nephrol Dial Transplant, 2013, 28(9):2268-2276.
|
| 28 |
Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy [J]. J Am Soc Nephrol, 2007, 18(12):3177-3183.
|
| 29 |
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney Inter Suppl, 2012, 2(2):139-274.
|
| 30 |
Praga M, Gutierrez E, Gonzalez E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial [J]. J Am Soc Nephrol, 2003, 14(6):1578-1583.
|
| 31 |
Yang F, Li B, Cui W, et al. A clinicopathological study of renal biopsies from 288 elderly patients: analysis based on 4，185 cases [J]. Int Urol Nephrol, 2015, 47(2):327-333.
|
| 32 |
Liu X, Dewei D, Sun S, et al. Treatment of severe IgA nephropathy: mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone [J]. Int J Clin Pharmacol Ther, 2014, 52(2):95-102.
|
| 33 |
Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy [J]. Clin Nephrol, 1999, 51(3):147-152.
|
| 34 |
Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy [J]. Kidney Int, 2003, 63(5):1861-1867.
|
| 35 |
Maeda I, Hayashi T, Sato KK, et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy [J]. Nephrol Dial Transplant, 2012, 27(7):2806-2813.
|
| 36 |
Hoshino Y, Moriyama T, Uchida K, et al. Comparison of oral steroids with tonsillectomy plus steroid pulse therapy in patients with IgA nephropathy [J]. Clin Exp Nephrol, 2016, Epub ahead of print.
|
| 37 |
Donadio JV, Grande JP. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy [J]. Semin Nephrol, 2004, 24(3):225-243.
|
| 38 |
Donadio JV Jr., Grande JP, Bergstralh EJ, et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial [J]. J Am Soc Nephrol, 1999, 10(8):1772-1777.
|
| 39 |
Fukuda M, Hotta O, Mizuno M, et al. Immunosuppressive therapy for active IgA nephropathy is effective and safe, even in "elderly" patients [J]. Clin Exp Nephrol, 2016, Epub ahead of print.
|
| 40 |
Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial [J]. J Am Soc Nephrol, 2004, 15(1):157-163.
|
| 41 |
Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial [J]. Am J Kidney Dis, 2009, 53(1):26-32.
|
| 42 |
Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy [J]. Nephrol Dial Transplant, 2009, 24(12):3694-3701.
|
| 43 |
Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy [J]. N Engl J Med, 2015, 373(23):2225-2236.
|
| 44 |
Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy [J]. J Am Soc Nephrol, 2010, 21(10):1783-1790.
|
| 45 |
Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy [J]. J Am Soc Nephrol, 2002, 13(1):142-148.
|
| 46 |
Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide [J]. Nephrol Dial Transplant, 2003, 18(7):1321-1329.
|
| 47 |
Shin JH, Lee JE, Park JH, et al. The effects of cytotoxic therapy in progressive IgA nephropathy [J]. Ann Med, 2016, 48(3):171-181.
|
| 48 |
Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial [J]. Nephrol Dial Transplant, 2005, 20(10):2139-2145.
|